[
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b9fa9a89d68bf0eed5c12ffcdccd829e3c6670303b92dc79bc37995eaf5b88da",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732293720,
      "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "id": 131601741,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b9fa9a89d68bf0eed5c12ffcdccd829e3c6670303b92dc79bc37995eaf5b88da"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Upgrading To 'Strong Buy' After Pullback",
    "summary": "AbbVieâs high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.",
    "url": "https://finnhub.io/api/news?id=0df10e1bcbeba0158dcbfaf1a9f8e50e0b4cf1c080a74bf9c7b958beb9447381",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732288243,
      "headline": "AbbVie: Upgrading To 'Strong Buy' After Pullback",
      "id": 131571049,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153992734/image_2153992734.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "AbbVieâs high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.",
      "url": "https://finnhub.io/api/news?id=0df10e1bcbeba0158dcbfaf1a9f8e50e0b4cf1c080a74bf9c7b958beb9447381"
    }
  },
  {
    "ts": null,
    "headline": "Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program",
    "summary": "In a regulatory filing on Wednesday, Hookipa Pharma (HOOK) announced that on November 18, the company approved a plan to continue to improve its cost structure and operating efficiency, which includes a reduction in the company’s workforce by approximately 80% of the company’s then-current employee base. The company expects to begin the implementation of the Restructuring Plan in the fourth quarter of 2024 and expects the Restructuring Plan to be substantially completed by the end of the first h",
    "url": "https://finnhub.io/api/news?id=3b27fbc1502641d0ed2d3bb31fd14cd31cfd1721177eeeafdb974ef28ce844fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732275353,
      "headline": "Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program",
      "id": 131562925,
      "image": "https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "In a regulatory filing on Wednesday, Hookipa Pharma (HOOK) announced that on November 18, the company approved a plan to continue to improve its cost structure and operating efficiency, which includes a reduction in the company’s workforce by approximately 80% of the company’s then-current employee base. The company expects to begin the implementation of the Restructuring Plan in the fourth quarter of 2024 and expects the Restructuring Plan to be substantially completed by the end of the first h",
      "url": "https://finnhub.io/api/news?id=3b27fbc1502641d0ed2d3bb31fd14cd31cfd1721177eeeafdb974ef28ce844fd"
    }
  }
]